Iron is essential for brain development, and poor iron status early in life is associated with lasting disruptions in cognitive and behavioral development (1) (2) (3) . In a study assessing the global and national burden of diseases in children, iron deficiency anemia was identified as a leading cause of years lived with disability in children and adolescents, affecting >600 million children in 2013 (4) . Similarly, malaria is a global public health problem with devastating effects on children, particularly in Africa. For example, malaria is a leading cause of school absenteeism (5) , and it causes 50% of deaths in school-aged children in sub-Saharan Africa (6) .
Research studies have identified a potential link between iron status and the frequency of malarial infections and associated morbidities. In a large randomized, placebo-controlled trial (n = ;8000/group), Sazawal et al. (7) found that routine supplementation with iron and folic acid in children aged 1-35 mo with high rates of malaria was associated with an increased risk of illness and death. Others found that poor iron status was associated with a reduced risk of parasitemia, severe malaria, allcause mortality, and malaria-associated mortality (8, 9) . It has been hypothesized that poor iron status and/or the sequestration of iron because of the physiologic actions of hepcidin in response to inflammation may protect against malaria and its associated morbidities by restricting the availability of iron to the parasitic infection (10) . Importantly, a recent Cochrane review (11) sought to evaluate the safety and efficacy of iron supplementation in children living in malaria-endemic areas. This study included 35 trials (31,955 children) and concluded that iron did not cause an excess of clinical malaria in populations in which anemia was common or in areas in which anemia was less common. Of note, study data indicate that in areas with prevention and management services for malaria, iron supplementation (with or without folic acid) may reduce clinical malaria. Notably, iron supplementation did not cause an excess of severe malaria, and was not associated with increased morbidity. The overall conclusion was that iron treatment does not increase the risk of clinical malaria when regular malaria prevention or management services are provided, and that iron supplementation can be provided without screening for iron status when malaria prevention or management services are used. WHO recommendations are reflective of these findings, and indicate that iron supplementation is recommended as a public health intervention for the prevention of poor iron status in infants and young children living in areas in which anemia is prevalent (12) . The WHO notes that in malaria-endemic regions, the provision of iron supplements should occur in conjunction with public health measures to prevent, diagnose, and treat malaria.
Because of reports associating poor iron status with protection against malaria and its morbidities, as well as remaining questions regarding the role of the inflammatory response in affecting iron absorption and the pathophysiology of malaria, important research questions remain regarding the timing of iron treatment in conjunction with antimalarial treatment. In a manuscript published in this issue of The Journal of Nutrition, Cusick et al. (13) tested the hypothesis that iron incorporation into red blood cells would be affected by the timing of the initiation of iron supplementation after the onset of antimalarial treatment. In this randomized clinical trial, 100 Ugandan children (aged 6-59 mo) with poor iron status (hemoglobin concentration between 50.0 and 99.9 g/L) and a positive Giemsa smear for Plasmodium falciparum were randomly assigned to receive a 27-d course of iron supplementation [liquid oral sulfate syrup, 2 mg/(kg Á d) either immediately after antimalarial treatment (parenteral artesunate) or 4 wk after the antimalarial treatment]. On study days 0, 28, and 56, blood was collected for assessment of iron status and inflammation. Iron incorporation into red blood cells was assessed with the use of stable isotopes ( 57 Fe and 58 Fe). The major finding of the study was that the mean percentage iron incorporation into red blood cells was greater on day 28 in the group that began iron supplementation 4 wk after antimalarial treatment than it was in the group that received concomitant iron supplementation and antimalarial treatment. However, on day 28, iron status was worse in the group that received delayed iron supplementation than it was in the group that received immediate iron supplementation, and, on day 56, iron status was equivalent between the groups. These data indicate that delaying the start of iron supplementation may improve iron incorporation into red blood cells, but it leads to equivalent hematological recovery by day 56. In sum, the data do not demonstrate a benefit of delaying iron supplementation in children with poor iron status and malaria.
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iron incorporation into red blood cells in the group that received delayed iron supplementation, in contrast to earlier studies suggesting that hepcidin may be the most consistent predictor of iron incorporation in children with anemia (14) . Further research is necessary to better understand the balance of factors (i.e., iron status, inflammation, and use of fortified foods or micronutrient powders) affecting the temporal response to iron supplementation. Most importantly, morbidity was not significantly different between study groups, although there was a trend toward increased return visits to the health clinic in the group that received immediate concomitant iron supplementation and antimalarial treatment. As such, future trials must be statistically powered to assess morbidity after immediate or delayed onset of iron supplementation. Similarly, if delaying iron supplementation were to prevent morbidity, ethical questions would remain regarding the acceptability of transiently poor iron status during early childhood, especially given the critical role of iron in brain development and the lasting effects of poor iron status early in life (1) (2) (3) .
The importance of identifying methods to optimize iron status for brain development in young children while protecting against malaria and its associated morbidities cannot be understated. Data from the study by Cusick et al. (13) bring the field one step closer to understanding the potential benefits of concomitant iron and antimalarial therapy, although important research and ethical questions remain with regard to the balance between iron needs for early childhood development and the prevention of malaria and its associated morbidity.
